**Table 1.** Baseline clinical characteristics of the study population

|  |  |
| --- | --- |
|  | All  N: 196 (%) |
| Age (years, median, IQR)  Sex  Male  Female  Diagnosis  Malignant disorders  PIDa  Other nonmalignant disorders  Donor  Related  Unrelated  Autologous  HLAb match  Well matched (10/10)  Partially matched (9/10)  Mismatched (≤8/10)  Autologous  Transplantation  Allogeneic  Autologous  Conditioning  Myeloablative  Reduced  None  GVHDc prophylaxis  Calcineurin inhibitor based (except PTCyd)  PTCy plus others  Others  None  T-cell depletion (in vivo or ex vivo)  aGVHD Grade ≥2 at COVID-19 diagnosis  cGVHD at COVID-19 diagnosis  Corticosteroid at COVID-19 diagnosis  Comorbidity | 8.75 (4.86-14.30)  125 (63.8)  71 (36.2)  120 (61.2)  25 (12.8)  51 (26)  102 (52.0)  82 (41.8)  12 (6.1)  112 (57.1)  45 (23.0)  27 (13.8)  12 (6.1)  184 (93.9)  12 (6.1)  178 (90.8)  17 (8.7)  1 (0.5)  150 (76.5)  30 (15.3)  4 (2.0)  12 (6.1)  53 (27.0)  49 (25.0)  11 (5.6)  60 (30.6)  51 (26.0) |

a*PID*, Primary immunodeficiency; b*HLA*, Human leukocyte antigen; c*GVHD*, Graft-versus-host disease; d*PTCy*, Posttransplant cyclophosphamide